Composition for regulating gastrointestinal function and application thereof

Abstract

The invention provides a composition for regulating gastrointestinal functions and application thereof. On the first aspect, the invention provides the composition for regulating the gastrointestinal function. The composition comprises 2-50 parts by mass of a pericarpium citri reticulatae extract and 2-50 parts by mass of a poria cocos extract; the mass ratio of the pericarpium citri reticulatae extract to the poria cocos extract is 1: (1-2). According to the composition provided by the invention, the synergistic interaction effect of all the components is realized through reasonable low-dose proportioning, and the composition is beneficial to promoting gastrointestinal peristalsis, improving gastrointestinal inflammation, relieving dyspepsia and repairing gastrointestinal mucosal lesion, especially promoting gastrointestinal peristalsis and eliminating gastrointestinal inflammation; moreover, the composition provided by the invention is derived from medicinal and edible substances and other plant extracts capable of being used in food, has the characteristics of high safety, small side effect, strong effect, good taste and flavor and the like, and can play a role in regulating the gastrointestinal function to the greatest extent by adding a relatively low dosage of the composition.

Description

Technical Field

[0001] The invention relates to a composition for regulating gastrointestinal function and application thereof, and relates to the technical field of food. Background Art

[0002] Functional dyspepsia (FD) is a digestive system disease with epigastric pain, early satiety, postprandial discomfort, and epigastric burning as the main symptoms. Although FD is a non-organic disease, it has the characteristics of a long course and easy recurrence. The pathogenesis of FD is still unclear, but existing studies have shown that FD is related to gastrointestinal motility and sensitivity, brain-gut axis dysfunction, Helicobacter pylori infection, social and psychological factors, intestinal flora, and genetic factors.

[0003] Regulating gastrointestinal function is one of the means to prevent and treat FD. However, the existing gastrointestinal health composition formula is relatively complex, and the proportion of Chinese herbal medicine ingredients is relatively large, which affects the taste and flavor of the product. Summary of the invention

[0004] The invention provides a composition for regulating gastrointestinal function, which can achieve the effect of regulating gastrointestinal function at a lower dosage, simplify the formula of the composition, and improve the taste and flavor.

[0005] The present invention also provides application of the above composition in preparing products for regulating gastrointestinal function.

[0006] The first aspect of the present invention provides a composition for regulating gastrointestinal function, comprising 2-50 parts by weight of tangerine peel extract and 2-50 parts by weight of Poria cocos extract; the mass ratio of the tangerine peel extract to the Poria cocos extract is 1:(1-2).

[0007] The invention provides a composition, comprising tangerine peel extract and Poria cocos extract, wherein tangerine peel is the dried mature peel of Rutaceae plant (Citrus reticulata Blanco) and its cultivars, and is rich in multiple medicinal active ingredients, such as volatile oils such as D-limonene, β-myrcene, α-pinene, flavonoids such as hesperidin, neohesperidin, tangerin, and multiple trace elements. Modern pharmacological studies have shown that tangerine peel has multiple pharmacological effects such as antibacterial, anti-inflammatory, anti-oxidant, digestion-promoting, liver-protecting, and blood pressure-lowering, and in particular, polymethoxyflavonoid compounds (nobiletin and tangerin) in tangerine peel have a relatively obvious digestion-promoting ability, and can promote the propulsion movement of the small intestine of normal mice and enhance the function of intestinal peristalsis. Poria cocos is the dried sclerotium of the polyporaceae fungus Poria cocos (Schw.) Wolf, which is a commonly used Chinese medicine in clinical practice. According to the Compendium of Materia Medica, Poria cocos is sweet, light, and flat in nature and flavor, and it is beneficial to the heart, lung, spleen, and kidney meridians, and has the effects of water penetration, spleen strengthening, and tranquilization of the heart. Modern studies have shown that the polysaccharides, triterpenes, and pachymic acid in Poria cocos can improve gastrointestinal symptoms through anti-inflammatory, regulating gastrointestinal motility, and regulating intestinal microecology. Therefore, the composition provided by the present invention realizes the synergistic effect of each component through a low-dose reasonable ratio, which helps to promote gastrointestinal motility, improve gastrointestinal inflammation, relieve indigestion, repair gastrointestinal mucosal damage, especially promote gastrointestinal motility and eliminate gastrointestinal inflammation. Moreover, the composition provided by the present invention comes from a medicine-food homologous substance, and has the characteristics of high safety, small side effects, strong efficacy, good taste and flavor, and the synergistic effect of regulating gastrointestinal function is maximized at a lower dose, especially promoting gastrointestinal motility and improving gastrointestinal inflammation.

[0008] The composition provided by the present invention does not contain any Chinese medicinal material component, thus avoiding the influence of the Chinese medicinal materials on the taste and flavor of the product to a great extent.

[0009] Further, the above composition includes 4-20 parts by weight of tangerine peel extract and 8-20 parts by weight of Poria cocos extract. For example, the weight of tangerine peel extract in the composition is one of 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 parts by weight, and the weight of Poria cocos is one of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 parts by weight.

[0010] In a specific embodiment, the above-mentioned composition also includes plant extracts that can be used in food in addition to tangerine peel extract and Poria cocos extract. Plant extract refers to a substance extracted or processed with plants (all or part of a plant) as raw materials using appropriate solvents or methods; specifically, the plant extract is selected from one or more of red ginseng extract, hawthorn extract, yam extract, hericium erinaceus extract, wolfberry extract, dandelion extract, lentinan, licorice extract, kudzu root extract, red date extract, coix seed extract, mulberry extract, wheat oligopeptide, ginger extract, and blueberry extract.

[0011] Specifically, the composition further comprises 5-15 parts by weight of Hericium erinaceus extract, i.e. Hericium erinaceus extract is added on the basis of tangerine peel extract and Poria cocos extract. For example, the composition further comprises Hericium erinaceus extract on the basis of tangerine peel extract and Poria cocos extract, and the Hericium erinaceus extract comprises one of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, and 15 parts by weight.

[0012] Hericium erinaceus is rich in minerals, vitamins, unsaturated fatty acids, and polysaccharides. According to the Compendium of Materia Medica, Hericium erinaceus is mild in nature and sweet in taste; it benefits the five internal organs and aids digestion; it has the effects of strengthening the spleen and stomach and treating physical weakness. Clinical experiments have shown that Hericium erinaceus has the effects of protecting gastric mucosa, improving cellular immune function, resisting Helicobacter pylori, and preventing gastritis.

[0013] Furthermore, the mass ratio of tangerine peel extract, Poria cocos extract and Hericium erinaceus extract is (0.5-2):(1-2):1.

[0014] Specifically, the composition further comprises 1-5 parts by mass of wheat oligopeptide, i.e., wheat oligopeptide is added on the basis of tangerine peel extract and Poria cocos extract. For example, the composition further comprises wheat oligopeptide on the basis of tangerine peel extract and Poria cocos extract, and the mass fraction of wheat oligopeptide is one of 1, 2, 3, 4, and 5 parts by mass.

[0015] Wheat oligopeptides are wheat protein hydrolysates, which are small molecule fragments obtained by protease hydrolysis of wheat protein (gluten powder). By hydrolyzing wheat protein with protease, its original nutritional value and physiological functions are improved to varying degrees. Glutamine, the active ingredient in wheat oligopeptides, is a special nutrient for gastrointestinal mucosal cells. Under stress, glutamine is almost the only source of energy required for gastrointestinal mucosal metabolism. It can improve intestinal immunity, reduce intestinal permeability, and maintain intestinal mucosal structure to protect the gastrointestinal mucosa.

[0016] Furthermore, the mass ratio of the tangerine peel extract, the Poria cocos extract, and the wheat oligopeptide is (4-16):(8-16):1.

[0017] The tangerine peel extract, Poria cocos extract and Hericium erinaceus extract mentioned in the present invention can be extracted by conventional technical means in the art or purchased from commercial products; wheat oligopeptides can also be obtained by hydrolyzing wheat protein according to conventional technical means in the art, for example, using trypsin, neutral protease, immobilized alkaline protease, etc. to hydrolyze wheat protein.

[0018] During the preparation process, the required raw materials are fully mixed according to the mass ratio to obtain the above-mentioned composition with gastrointestinal regulating function.

[0019] The second aspect of the present invention provides the use of any of the above-mentioned compositions in products for regulating gastrointestinal function.

[0020] In a specific embodiment, the product is one or more of food, health care product, and medicine.

[0021] Furthermore, the product is a food, and the food is preferably one or more of milk powder, fermented milk, milk drink, solid beverage, and probiotic product.

[0022] In a specific embodiment, the composition provided by the present invention has the effect of regulating gastrointestinal function by promoting gastrointestinal motility, protecting gastrointestinal mucosa, and improving gastrointestinal inflammation. Based on the different components contained in the composition, different compositions have different effects in the above three aspects, and the minimum effective dose of the composition is also different; specifically, the effective dose of the composition in promoting gastrointestinal motility is not less than 1.38g / d; the effective dose of the composition in protecting gastrointestinal mucosa and improving gastrointestinal inflammation is not less than 0.54g / d.

[0023] It should be noted that the effective dose referred to in the present invention refers to the minimum effective mass of the composition taken daily, and the effective dose is calculated based on a 60 kg human body. When the weight of the human body changes, the dosage of the composition can be appropriately adjusted as needed.

[0024] The present invention has no special restrictions on the preparation method of the product with gastrointestinal regulating function. The composition with gastrointestinal regulating function provided by the first aspect of the present invention can be added during the product preparation process. During the addition process, it is necessary to ensure that the active substances in each extract are not destroyed.

[0025] The composition provided by the present invention achieves the synergistic effect of each component through a low-dose and reasonable ratio, which is helpful to promote gastrointestinal motility, improve gastrointestinal inflammation, relieve indigestion, and repair gastrointestinal mucosal damage, especially promote gastrointestinal motility and eliminate gastrointestinal inflammation; and the composition provided by the present invention is derived from medicinal and edible substances and plant extracts that can be used in food, and has the characteristics of high safety, small side effects, strong efficacy, good taste and flavor, etc., and maximizes the effect of regulating gastrointestinal function by adding at a relatively low dose. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] Figure 1a The gastrointestinal fluorescence intensity phenotype of zebrafish treated with the compositions provided in Examples 1-3 and Comparative Examples 1-4;

[0027] Figure 1b A histogram of the fluorescence intensity of the gastrointestinal tract of zebrafish after being treated with the compositions provided in Examples 1-3 and Comparative Examples 1-4;

[0028] Figure 2a The gastrointestinal tract area phenotype diagram of zebrafish treated with the compositions provided in Examples 1-5 and Comparative Examples 1-4 and 7;

[0029] Figure 2b A histogram of the gastrointestinal tract area of ​​zebrafish treated with the compositions provided in Examples 1-5 and Comparative Examples 1-4 and 7;

[0030] Figure 3a The phenotype diagram of the number of gastrointestinal neutrophils in zebrafish treated with the compositions provided in Examples 4-5 and Comparative Examples 5-7;

[0031] Figure 3b A bar graph showing the number of gastrointestinal neutrophils in zebrafish treated with the compositions provided in Examples 4-5 and Comparative Examples 5-7. DETAILED DESCRIPTION

[0032] In order to make the purpose, technical solutions and advantages of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below in combination with the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0033] Unless otherwise specified, the components used in the following examples and comparative examples are all commercially available products.

[0034] Example 1

[0035] The composition provided in this embodiment includes 20 parts by weight of tangerine peel extract and 20 parts by weight of Poria cocos extract.

[0036] Example 2

[0037] The composition provided in this embodiment includes 16 parts by weight of tangerine peel extract, 16 parts by weight of Poria cocos extract, and 8 parts by weight of Hericium erinaceus extract.

[0038] Example 3

[0039] The composition provided in this embodiment includes 16 parts by mass of tangerine peel extract, 16 parts by mass of Poria cocos extract and 1 part by mass of wheat oligopeptide.

[0040] Example 4

[0041] The composition provided in this embodiment includes 4 parts by mass of tangerine peel extract, 8 parts by mass of Poria cocos extract and 1 part by mass of wheat oligopeptide.

[0042] Example 5

[0043] The composition provided in this embodiment includes 8 parts by weight of tangerine peel extract and 12 parts by weight of Poria cocos extract.

[0044] Comparative Example 1

[0045] The composition provided in this comparative example is 40 parts by weight of Hericium erinaceus extract.

[0046] Comparative Example 2

[0047] The composition provided in this comparative example is 72 parts by weight of Poria cocos extract.

[0048] Comparative Example 3

[0049] The composition provided in this comparative example is 36 parts by weight of tangerine peel extract.

[0050] Comparative Example 4

[0051] The composition provided in this comparative example is 36 parts by mass of wheat oligopeptide.

[0052] Comparative Example 5

[0053] The composition provided in this comparative example is 18 parts by weight of Poria cocos extract.

[0054] Comparative Example 6

[0055] The composition provided in this comparative example is 18 parts by weight of tangerine peel extract.

[0056] Comparative Example 7

[0057] The composition provided in this comparative example is 13 parts by mass of wheat oligopeptide.

[0058] Experimental Example 1 Evaluation of Gastrointestinal Motility Improvement Effect

[0059] 1. Experimental samples

[0060] Examples 1-3 and Comparative Examples 1-4 provide compositions.

[0061] Positive control: Domperidone tablets, white tablets, batch number 190104499, Xi'an Janssen Pharmaceutical Co., Ltd., stored in a cool place. Prepared into 10.0 mg / mL stock solution with DMSO, stored at -20°C.

[0062] 2. Experimental Animals

[0063] Wild-type AB strain zebrafish: Breeding was carried out by natural pair mating. Zebrafish aged 3 days post fertilization (3 dpf), 30 fish per experimental group.

[0064] Zebrafish were raised in fish farming water at 28°C (water quality: 200 mg of instant sea salt was added to every 1 L of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO3), bred and provided by the fish farming center of Hangzhou Huante Biotechnology Co., Ltd., and the breeding and management met the requirements of the international AAALAC certification.

[0065] 3. Instruments and reagents

[0066] Dissecting microscope (SZX7, OLYMPUS, Japan); CCD camera (VertA1, Shanghai Tusen Vision Technology Co., Ltd., China); motorized focus continuous zoom fluorescence microscope (AZ100, Nikon, Japan); precision electronic balance (CP214, OHAUS, USA); 6-well plate (Nest Biotech, China); dimethyl sulfoxide (DMSO, batch number BCCD8942, Sigma, Switzerland); trinitrobenzene sulfonic acid (TNBS, batch number SLCK4178, Sigma, USA); methylcellulose (batch number C2004046, Shanghai Aladdin Biochemical Technology Co., Ltd., China); Nile red (batch number SLBP9326V, Sigma, India).

[0067] 4. Experimental methods

[0068] Gastrointestinal motility improvement efficacy experiment: 3dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). Except for the normal control group, the remaining experimental groups were given TNBS in water to establish a zebrafish indigestion model. After 2 days of treatment at 28°C, TNBS was removed and Nile red was given in water as a fluorescent indicator of intestinal contents. After feeding, the zebrafish were randomly assigned to a 6-well plate, and 30 zebrafish were treated in each well (experimental group). The drug administration was carried out according to the dosage concentration of the comparative example and the embodiment, and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. 28°C was treated to 7dpf, and 10 zebrafish were randomly selected from each group to take pictures under a fluorescence microscope and save the pictures. The NIS-ElementsD 3.20 advanced image processing software was used to analyze and collect data, and the zebrafish gastrointestinal fluorescence intensity (S) was analyzed. The statistical analysis results of this indicator were used to evaluate the gastrointestinal motility improvement efficacy of the samples.

[0069] In the study of gastrointestinal motility, zebrafish were fed with specific fluorescent dyes that could not be absorbed by the gastrointestinal tract. The slower the gastrointestinal motility of the zebrafish, the stronger the intensity of the fluorescent dye in the zebrafish. Figure 1a-1b As shown in Table 1, compared with the model control, the fluorescence intensity in the gastrointestinal tract of zebrafish in Examples 1-3 and Comparative Example 3 was significantly weakened (P < 0.001), and the fluorescence intensity in the gastrointestinal tract of zebrafish in Examples 1-3 was weaker than that in Comparative Examples 1-2 and Comparative Example 4. The fluorescence intensity in the gastrointestinal tract of zebrafish in Comparative Example 3 was the weakest, indicating that the single sample of tangerine peel extract had a more prominent effect in alleviating gastrointestinal motility, but the cost of tangerine peel extract was relatively high, comparable to the price of Hericium erinaceus extract, and 1.6-2 times the price of Poria cocos extract and wheat oligopeptide. Therefore, considering the cost and gastrointestinal motility improvement effect, Example 3 was determined to be the optimal ratio.

[0070] Table 1 Gastrointestinal motility improvement test results of the compositions provided by Examples 1-3 and Comparative Examples 1-4

[0071] Group Zebrafish intervention dose (μg / mL) Gastrointestinal fluorescence intensity (pixels) Normal control group / 294378±6668*** Model control group / 496239±20206 Positive control (morphine) 87.5 236246±11278*** Example 1 139+139 348646±11407*** Example 2 111+111+55.6 328188±19960*** Example 3 111+111+6.94 319828±7342*** Comparative Example 1 278 449907±29253 Comparative Example 2 500 430599±22388 Comparative Example 3 250 305609±10330*** Comparative Example 4 250 387509±11942**

[0072] Among them, ** indicates P < 0.01, *** indicates P < 0.001.

[0073] Experimental Example 2 Evaluation of the repair effect of gastrointestinal mucosal damage

[0074] 1. Experimental samples

[0075] Samples prepared in Examples 1-5 and Comparative Examples 1-4 and 7

[0076] Positive control: prednisone, white powder, batch number C10016501, Shanghai MacLean Biochemical Technology Co., Ltd., stored at 4°C. Prepared into 15.0 mg / mL stock solution with DMSO and stored at -20°C.

[0077] 2. Experimental Animals

[0078] Same as Experimental Example 1.

[0079] 3. Instruments and reagents

[0080] Same as Experimental Example 1.

[0081] 4. Experimental methods

[0082] Evaluation of the repair efficacy of gastrointestinal mucosal damage: 3dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). Except for the normal control group, the remaining experimental groups were given TNBS in water to establish a zebrafish gastrointestinal mucosal damage model. After 2 days of treatment at 28°C, TNBS was removed, and 30 zebrafish were treated in each well (experimental group). The drug treatment was carried out according to the dosage concentration of the comparative example and the embodiment, and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. After 2 days of treatment at 28°C, 10 zebrafish were randomly selected from each experimental group and placed under a dissecting microscope for photographing. NIS-Elements D 3.20 advanced image processing software was used to collect data, and the zebrafish gastrointestinal area (A) was analyzed. The statistical analysis results of this indicator were used to evaluate the repair efficacy of the sample gastrointestinal mucosal damage.

[0083] 5. Experimental results

[0084] In the evaluation of gastrointestinal mucosal injury repair efficacy, TNBS can destroy the gastrointestinal mucosal barrier, combine with intestinal tissue proteins to form antigens, cause allergic reactions, and induce ulcerative gastrointestinal injury. Gastrointestinal lesions involve the muscular layer and nerves, resulting in decreased gastrointestinal wall tension and expansion of the gastrointestinal cavity. By analyzing the gastrointestinal tract area, the improvement effect of the test product on gastrointestinal mucosal injury can be evaluated. The experimental results are as follows: Figure 2a-2b As shown in Table 2, it can be seen that the gastrointestinal area of ​​Examples 1-5 is significantly reduced compared with the model group (P < 0.001). Among them, Examples 1-2 have a synergistic effect compared with Comparative Examples 1-3, and the gastrointestinal mucosal repair rate is better than that of Comparative Examples 1-3. Although Comparative Example 4 has the best effect in gastrointestinal mucosal repair, the bitter taste of wheat oligopeptides itself limits its application in products, so the development of low-dose compositions has shown its advantages. Examples 4-5 have synergistic effects at lower doses, and the effects of these two compositions are significantly better than those of Comparative Example 2, and there is no significant difference compared with Comparative Examples 3 and 7.

[0085] Table 2 Experimental results of the gastrointestinal mucosal damage repair effect of the compositions provided in Examples 1-5 and Comparative Examples 1-4 and 7

[0086] Group Zebrafish intervention dose (μg / mL) Gastrointestinal tract area (pixels) Normal control group / 82020±2249*** Model control group / 139315±3453 Positive control (prednisone) 15.0 96574±1931*** Example 1 139+139 92507±2931*** Example 2 111+111+55.6 91770±2091*** Example 3 111+111+6.94 92631±2553*** Example 4 27.8+55.6+6.94 95938±3058*** Example 5 55.6+83.3 93631±3543*** Comparative Example 1 278 94825±1268*** Comparative Example 2 500 126252±4675 Comparative Example 3 250 96731±2107*** Comparative Example 4 250 80945±1224*** Comparative Example 7 90.3 92329±2070***

[0087] Among them, *** indicates P < 0.001.

[0088] Experimental Example 3 Evaluation of the efficacy of relieving gastrointestinal inflammation

[0089] 1. Experimental samples

[0090] Examples 4-5 and Comparative Examples 5-7 provide compositions.

[0091] Positive control: prednisone, white powder, batch number C10016501, Shanghai MacLean Biochemical Technology Co., Ltd., stored at 4°C. Prepared into 15.0 mg / mL stock solution with DMSO and stored at -20°C.

[0092] 2. Experimental Animals

[0093] Transgenic neutrophil fluorescent zebrafish (MPX): zebrafish aged 3 dpf.

[0094] 3. Instruments and reagents

[0095] Same as Experimental Example 1.

[0096] 4. Experimental methods

[0097] Gastrointestinal inflammation relief efficacy experiment: 3dpf transgenic neutrophil green fluorescent zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well (experimental group). Except for the normal control group, the remaining experimental groups were given TNBS in water to establish a zebrafish gastrointestinal mucosal injury model. After 2 days of treatment at 28°C, TNBS was removed, and 30 zebrafish were treated in each well (experimental group). The drug treatment was carried out according to the dosage concentration of the comparative example and the embodiment, and a normal control group and a model control group were set up at the same time, with a capacity of 3mL per well. After 2 days of treatment at 28°C, 10 zebrafish were randomly selected from each experimental group and placed under a fluorescence microscope for photography. NIS-Elements D 3.20 advanced image processing software was used to collect data, and the number of zebrafish gastrointestinal neutrophils (N) was analyzed. The statistical analysis results of this indicator were used to evaluate the efficacy of the sample in relieving gastrointestinal inflammation.

[0098] 5. Experimental results

[0099] Inflammatory reactions occur when there are gastrointestinal lesions, neutrophils are recruited to the site of injury, and the number of neutrophils increases. Figure 3a-3bAs shown in Table 3, it can be seen that compared with the model control group, the number of gastrointestinal neutrophils after treatment with the embodiment and the comparative example was significantly reduced (P < 0.001), and the improvement effect of the embodiment on gastrointestinal inflammation was improved compared with the comparative example.

[0100] Table 3 Experimental results of the efficacy of the compositions provided in Examples 4-5 and Comparative Examples 5-7 in alleviating gastrointestinal inflammation

[0101] Zebrafish intervention dose (μg / mL) The number of neutrophils in the gastrointestinal tract (mean ± SE) Normal control group / 7.70±0.396*** Model control group / 18.8±0.359 Positive control (prednisone) 15.0 8.80±0.442*** Example 4 27.8+55.6+6.94 8.40±0.306*** Example 5 55.6+83.3 6.8±0.490*** Comparative Example 5 125 11.9±0.567*** Comparative Example 6 125 11.0±0.615*** Comparative Example 7 90.3 11.2±0.629***

[0102] Among them, *** indicates P < 0.001.

[0103] According to Experimental Examples 1-3, it is confirmed that the composition provided by the present invention can regulate gastrointestinal function by promoting gastrointestinal motility, protecting gastrointestinal mucosa, and improving gastrointestinal inflammation. Therefore, the present invention preliminarily calculates the minimum effective dose for humans based on the zebrafish and human dose conversion formula: zebrafish test concentration (μg / mL) × 6 / 1000 = human (based on 60 kg) daily dosage (g), specifically:

[0104] According to the data provided in Table 1, the minimum effective concentration in the zebrafish test is 111+111+6.94=228.94 μg / mL, which is converted into a human dose of 1.38 g / d, indicating that the minimum effective dose of the composition provided by the present invention for promoting gastrointestinal motility is 1.38 g / d.

[0105] According to the data provided in Table 2-3, the minimum effective concentration of the zebrafish test is 27.8+55.6+6.94=90.34 μg / mL, which is converted into a human dose of 0.54 g / d, indicating that the minimum effective dose of the composition provided by the present invention to improve gastrointestinal mucosal damage repair and inflammation is 0.54 g / d.

[0106] The minimum effective human dose provided by the present invention is calculated based on data from zebrafish experiments, and the specific dose-effect relationship needs to be further verified through animal experiments.

[0107] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A composition for regulating gastrointestinal function, characterized in that: The composition comprises 2-50 parts by weight of tangerine peel extract and 2-50 parts by weight of Poria cocos extract; the mass ratio of the tangerine peel extract to the Poria cocos extract is 1:(1-2).

2. The composition according to claim 1, characterized in that The composition comprises 4-20 parts by weight of tangerine peel extract and 8-20 parts by weight of Poria cocos extract.

3. The composition according to claim 1 or 2, characterized in that The composition also includes one or more of red ginseng extract, hawthorn extract, yam extract, hericium erinaceus extract, wolfberry extract, dandelion extract, lentinan, licorice extract, kudzu root extract, red date extract, coix seed extract, mulberry extract, wheat oligopeptide, ginger extract, and blueberry extract.

4. The composition according to claim 1 or 2, characterized in that The composition further comprises 5-15 parts by weight of Hericium erinaceus extract.

5. The composition according to claim 4, characterized in that The mass ratio of the tangerine peel extract, the Poria cocos extract and the Hericium erinaceus extract is (0.5-2):(1-2):

1.

6. The composition according to claim 1 or 2, characterized in that The composition further comprises 1-5 parts by mass of wheat oligopeptide.

7. The composition according to claim 6, characterized in that The mass ratio of the tangerine peel extract, the Poria cocos extract and the wheat oligopeptide is (4-16):(8-16):

1.

8. Use of the composition according to any one of claims 1 to 7 in the preparation of a product for regulating gastrointestinal function.

9. The use according to claim 8, characterized in that: The product is one or more of milk powder, fermented milk, milk beverage, solid beverage, and probiotic product.

10. The use according to claim 8, characterized in that: The effective dosage of the composition in promoting gastrointestinal motility is not less than 1.38 g / d; The effective dosage of the composition in protecting gastrointestinal mucosa and improving gastrointestinal inflammation is not less than 0.54 g / d.

Images